Related Experiment Video
Updated: Jan 27, 2026

Induction and Diverse Assessment Indicators of Experimental Autoimmune Encephalomyelitis
Published on: September 9, 2022
Lactobacillus reuteri Reduces the Severity of Experimental Autoimmune Encephalomyelitis in Mice by Modulating Gut
Baokun He1, Thomas K Hoang1, Xiangjun Tian2
1Division of Gastroenterology, Departments of Pediatrics, The University of Texas Health Science Center at Houston-McGovern Medical School, Houston, TX, United States.
Abstract:
The gut microbiome plays an important role in immune function and has been implicated in multiple sclerosis (MS). However, how and if the modulation of microbiota can prevent or treat MS remain largely unknown. In this study, we showed that probiotic Lactobacillus reuteri DSM 17938 (L. reuteri) ameliorated the development of murine experimental autoimmune encephalomyelitis (EAE), a widely used animal model of MS, a model which is primarily mediated by TH17 and TH1 cells. We discovered that L. reuteri treatment reduced TH1/TH17 cells and their associated cytokines IFN-γ/IL-17 in EAE mice. We also showed that the loss of diversity of gut microbiota induced by EAE was largely restored by L. reuteri treatment. Taxonomy-based analysis of gut microbiota showed that three "beneficial" genera Bifidobacterium, Prevotella, and Lactobacillus were negatively correlated with EAE clinical severity, whereas the genera Anaeroplasma, Rikenellaceae, and Clostridium were positively correlated with disease severity. Notably, L. reuteri treatment coordinately altered the relative abundance of these EAE-associated taxa. In conclusion, probiotic L. reuteri changed gut microbiota to modulate immune responses in EAE, making it a novel candidate in future studies to modify the severity of MS.
Insights
Probiotic Lactobacillus reuteri (L. reuteri) eased multiple sclerosis symptoms in a mouse model by reducing harmful immune cells and restoring gut bacteria diversity. This suggests L. reuteri may help manage MS severity.
Area of Science:
- Immunology
- Microbiology
- Neuroscience
Background:
- The gut microbiome influences immune function and is linked to multiple sclerosis (MS).
- The potential of microbiota modulation for MS prevention or treatment is largely unexplored.
Purpose of the Study:
- To investigate the therapeutic potential of probiotic Lactobacillus reuteri (L. reuteri) in experimental autoimmune encephalomyelitis (EAE), an animal model of MS.
- To determine the effects of L. reuteri on immune cell populations and gut microbiota composition in EAE.
Main Methods:
- Administration of L. reuteri DSM 17938 to mice with EAE.
- Assessment of T helper 1 (TH1) and T helper 17 (TH17) cell populations and their associated cytokines (IFN-γ, IL-17).
- Analysis of gut microbiota diversity and composition using 16S rRNA sequencing.
Main Results:
- L. reuteri treatment ameliorated EAE development and reduced TH1/TH17 cell responses and associated cytokines.
- EAE-induced loss of gut microbiota diversity was restored by L. reuteri treatment.
- Specific bacterial genera (Bifidobacterium, Prevotella, Lactobacillus) were negatively correlated with EAE severity, while others (Anaeroplasma, Rikenellaceae, Clostridium) were positively correlated. L. reuteri modulated these taxa.
Conclusions:
- Probiotic L. reuteri modulates gut microbiota and immune responses in the EAE model.
- L. reuteri demonstrates potential as a therapeutic candidate for modifying MS severity.
Related Concept Videos
Autoimmune Disorders
Concept and Mechanism of Autoimmune Diseases
The immune...
Reducing Line Loss
With a step-up transformer at the source, the voltage is increased, thereby reducing the current in the transmission lines since power loss in...
Methods of reducing fever
Pharmacological Methods of Reducing Fever:
Adaptations that Reduce Water Loss
Role of Reduced Coenzymes NADH and FADH₂
Redox Titration: Other Oxidizing and Reducing Agents

